Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

rade 3/4 elevated total bilirubin reported among atazanavir recipients in each of the groups, respectively. There were no opportunistic infections reported in the vicriviroc groups compared to two in the control group, and no systemic malignancies reported in any of the groups in the 48- week study.

These results supported the selection of the 30 mg once-daily vicriviroc dose for use in ongoing Phase III clinical studies.

About Vicriviroc Ongoing Phase III Studies

Building on the results of the VICTOR-E1 study, Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc administered once-daily as a single 30 mg tablet in adult treatment-experienced HIV patients with R5-type virus only.

The two ongoing Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies are currently enrolling approximately 375 patients each at more than 160 sites in North America, Latin America, Europe, Australia and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own bi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Home Care Assistance of Centennial , North ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/22/2014)... -- College can be a challenging time for young people, ... to make the most of their new life, an expert ... new people and learn to manage the temptations of new ... at St. John,s University in New York City, said in ... in the classroom. College is a time when students transition ...
(Date:8/22/2014)... ItsHot.com, a client-centric manufacturer, wholesaler and ... on its range of beautiful diamond heart pendants. Customers ... Hearts 14K White Rose Gold Diamond Heart Pendant, which ... 77%. Previously priced at $3,715.00, customers can now buy ... of this mesmerizing pendant embedded with 0.66 carats round ...
(Date:8/22/2014)... According to the new research report "Isocyanate Market ... Forecast to 2019" defines and segments the isocyanate ... market value. The isocyanate material market value will ... significant CAGR from 2014 to 2019. , Browse ... through 286 pages and in-depth TOC on "Isocyanate ...
(Date:8/22/2014)... approx. 265,000 Danes are acutely admitted to medical departments ... University and Aarhus University Hospital now shows that many ... are sent home again without receiving a diagnosis ... hospitalisation., "Naturally, there is no need for a diagnosis ... is a serious illness. So some patients will always ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2
... NHS hospital is, the higher the MRSA infection rate, research ... ,The impact of risk management standards on the frequency ... demanding risk management standards imposed by hospital insurers — and ... — could reduce MRSA infection rates. ,Institutions ...
... the US. Striking a blow for the pro-choice sections, New ... bill that would strengthen abortion rights. ,Only last ... Abortion Ban Act, signed by President Bush in 2003. The ... doctors say are often the safest and best to protect ...
... A team of researchers at the John Hopkins Hospital in the ... to the PSA to detect prostate cancer.// ,The new ... in a simple blood test. ,Prostate cancer, the ... areas of medicine. Physicians are unsure how to find it and ...
... little to maintaining one's health after all. A new UK study ... philosophically muse about flesh being heir to a thousand natural shocks, ... ,But the UK researchers point to a striking discrimination in the ... ages a person eight years earlier than high earners. ...
... food. That is a far more sensible way of fighting the ... , In fact prescription drugs to prevent diabetes cannot be ... ,Trials show rosiglitazone pills do work, but so does weight ... 2 diabetes, the researchers argue. ,In the British ...
... Research has shown a way for people suffering diabetic ... as alleviating the effects of diabetic retinopathy,// which is ... ,In the initial stages, retinopathy does not portray ... to cause the blood vessels of the eye to ...
Cached Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:New blood test to detect prostate cancer 2Health News:Lower the wages, the faster one ages, UK study shows 2Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... Cephalon, Inc. (NASDAQ: CEPH): In a letter ... stated that it "is presently undertaking a review of ... is focused on maximizing Cephalon shareholder value."  We know ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... to discuss first quarter 2011 financial results, as well as ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 ... ended March 31, 2011 will be released earlier that day. ...
Cached Medicine Technology:Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: